193 related articles for article (PubMed ID: 33155417)
1. Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
Casey M; Degtyarev E; Lechuga MJ; Aimone P; Ravaud A; Motzer RJ; Liu F; Stalbovskaya V; Tang R; Butler E; Sailer O; Halabi S; George D
Pharm Stat; 2021 Mar; 20(2):324-334. PubMed ID: 33155417
[TBL] [Abstract][Full Text] [Related]
2. Estimands in hematologic oncology trials.
Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
[TBL] [Abstract][Full Text] [Related]
3. Incorporating estimands into clinical trial statistical analysis plans.
Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
[TBL] [Abstract][Full Text] [Related]
4. Application of the Estimand Framework to Anesthesia Trials.
De Silva AP; Leslie K; Braat S; Grobler AC
Anesthesiology; 2024 Jul; 141(1):13-23. PubMed ID: 38743905
[TBL] [Abstract][Full Text] [Related]
5. Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
[TBL] [Abstract][Full Text] [Related]
6. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
Jin M; Liu G
Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
[TBL] [Abstract][Full Text] [Related]
7. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
[TBL] [Abstract][Full Text] [Related]
8. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
[TBL] [Abstract][Full Text] [Related]
9. Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development.
Englert S; Mercier F; Pilling EA; Homer V; Habermehl C; Zimmermann S; Kan-Dobrosky N
Pharm Stat; 2023; 22(5):921-937. PubMed ID: 37403434
[TBL] [Abstract][Full Text] [Related]
10. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework.
Grobler AC; Lee KJ; Wong A; Currow DC; Braat S
J Pain Symptom Manage; 2022 Apr; 63(4):e431-e439. PubMed ID: 34954068
[TBL] [Abstract][Full Text] [Related]
11. Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.
Degtyarev E; Zhang Y; Sen K; Lebwohl D; Akacha M; Hampson LV; Bornkamp B; Maniero A; Bretz F; Zuber E
JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100723
[TBL] [Abstract][Full Text] [Related]
12. Application of estimand framework in ICH E9 (R1) to safety evaluation.
Wang X; Yang P; Yuan SS; Wang WWB
J Biopharm Stat; 2023 Jul; 33(4):476-487. PubMed ID: 36951445
[TBL] [Abstract][Full Text] [Related]
13. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
Rehal S; Cro S; Phillips PP; Fielding K; Carpenter JR
Clin Trials; 2023 Oct; 20(5):497-506. PubMed ID: 37277978
[TBL] [Abstract][Full Text] [Related]
14. A note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis.
Mehrotra DV
Clin Trials; 2019 Aug; 16(4):339-344. PubMed ID: 30977390
[TBL] [Abstract][Full Text] [Related]
15. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
Morga A; Latimer NR; Scott M; Hawkins N; Schlichting M; Wang J
Value Health; 2023 Feb; 26(2):234-242. PubMed ID: 36150999
[TBL] [Abstract][Full Text] [Related]
16. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Lawrance R; Degtyarev E; Griffiths P; Trask P; Lau H; D'Alessio D; Griebsch I; Wallenstein G; Cocks K; Rufibach K
J Patient Rep Outcomes; 2020 Aug; 4(1):68. PubMed ID: 32833083
[TBL] [Abstract][Full Text] [Related]
17. Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.
Mitroiu M; Teerenstra S; Oude Rengerink K; Pétavy F; Roes KCB
Pharm Stat; 2022 Sep; 21(5):1037-1057. PubMed ID: 35678545
[TBL] [Abstract][Full Text] [Related]
18. The attributable estimand: A new approach to account for intercurrent events.
Darken P; Nyberg J; Ballal S; Wright D
Pharm Stat; 2020 Sep; 19(5):626-635. PubMed ID: 32198954
[TBL] [Abstract][Full Text] [Related]
19. [What Is an Estimand?-The Most Important Clinical Question in Oncology Trials].
Hamasaki T; Bretz F
Gan To Kagaku Ryoho; 2022 Apr; 49(4):381-388. PubMed ID: 35444118
[TBL] [Abstract][Full Text] [Related]
20. Estimands in practice: Bridging the gap between study objectives and statistical analysis.
Phillips A; Clark T
Pharm Stat; 2021 Jan; 20(1):68-76. PubMed ID: 32893473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
